Lenvatinib
Phase 2Active 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hepatocellular Carcinoma
Conditions
Hepatocellular Carcinoma
Trial Timeline
Jul 20, 2023 → Nov 1, 2027
NCT ID
NCT06138769About Lenvatinib
Lenvatinib is a phase 2 stage product being developed by Eisai for Hepatocellular Carcinoma. The current trial status is active. This product is registered under clinical trial identifier NCT06138769. Target conditions include Hepatocellular Carcinoma.
What happened to similar drugs?
5 of 20 similar drugs in Hepatocellular Carcinoma were approved
Approved (5) Terminated (2) Active (14)
Hype Score Breakdown
Clinical
12
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03533361 | Pre-clinical | Completed |
| NCT02211222 | Pre-clinical | Completed |
| NCT05901194 | Phase 1/2 | Active |
| NCT06138769 | Phase 2 | Active |
| NCT05171335 | Phase 2 | Recruiting |
| NCT05103904 | Phase 2 | Recruiting |
| NCT04321954 | Phase 2 | Active |
| NCT04297254 | Approved | Completed |
| NCT04447755 | Phase 2 | Completed |
| NCT04008082 | Pre-clinical | Completed |
| NCT03506048 | Phase 2 | Terminated |
| NCT03009292 | Phase 1 | Completed |
| NCT03663114 | Pre-clinical | Completed |
| NCT02846766 | Phase 2 | Withdrawn |
| NCT03433703 | Phase 2 | Terminated |
| NCT03573960 | Approved | Completed |
| NCT03168074 | Phase 2 | UNKNOWN |
| NCT02953743 | Phase 1 | Completed |
| NCT02780310 | Phase 2 | Active |
| NCT02579616 | Phase 2 | Completed |
Competing Products
20 competing products in Hepatocellular Carcinoma